Bacillus Calmette-Guerin immunotherapy of infiltrating bladder cancer.
Oral administration of bacillus Calmette-Guerin was used to treat 10 patients with muscle invasive transitional cell carcinoma of the bladder. The treatment induced tumor regression in 7 patients (70 per cent), including 1 who died without evidence of recurrent tumor. Skin test reactivity was correlated with response to treatment. Only 1 patient had marked skin test reactivity at the time of tumor recurrence. Our data demonstrated that patients with invasive bladder cancer may derive benefit from immunotherapy.
D000368:Aged; D001500:BCG Vaccine / Q000008:administration & dosage / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D012882:Skin Tests; D001749:Urinary Bladder Neoplasms / Q000628:therapy*
D001500:BCG Vaccine